Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131266 | 0.92 | EPHX1 (0.45) | CHRM2CHRM1CHRM3EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL2798175 | 0.90 | EPHX1 (0.44) | CHRM2CHRM1CHRM3EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL2794765 | 0.90 | EPHX1 (0.44) | CHRM2CHRM1CHRM3EPHX1EPHX2 | |
| SCHEMBL14208049 | 0.87 | HPGDS (0.38) | EPHX1EPHX2KDM1ADPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL29191950 | 0.87 | CHRM2 (0.44) | CHRM2CHRM1CHRM3EPHX1EPHX2 | |
| SCHEMBL4634900 | 0.82 | EPHX1 (0.41) | CHRM2CHRM1CHRM3EPHX1EPHX2 | |
| SCHEMBL4634897 | 0.82 | EPHX1 (0.41) | CHRM2CHRM1CHRM3EPHX1EPHX2 | |
| SCHEMBL5511542 | 0.82 | EPHX1 (0.41) | CHRM2CHRM1CHRM3EPHX1EPHX2 | |
| Hydrochloric Acid SCHEMBL4635025 | 0.81 | EPHX1 (0.40) | CHRM2CHRM1CHRM3EPHX1EPHX2 | |
| SCHEMBL22596144 | 0.79 | EPHX1 (0.42) | EPHX1EPHX2KDM1ARIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748614-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105650-A1 | Substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | CHRM2 1519/4885CHRM1 1150/4885CHRM3 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.